Barclays PLC Raises Stock Holdings in LifeVantage Co. (NASDAQ:LFVN)

Barclays PLC grew its position in shares of LifeVantage Co. (NASDAQ:LFVN - Free Report) by 38.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 41,966 shares of the company's stock after purchasing an additional 11,608 shares during the period. Barclays PLC owned 0.34% of LifeVantage worth $507,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Renaissance Technologies LLC boosted its holdings in shares of LifeVantage by 2.1% during the second quarter. Renaissance Technologies LLC now owns 855,118 shares of the company's stock worth $5,490,000 after purchasing an additional 17,300 shares during the last quarter. Ritholtz Wealth Management boosted its stake in LifeVantage by 62.0% in the 3rd quarter. Ritholtz Wealth Management now owns 28,666 shares of the company's stock worth $346,000 after buying an additional 10,974 shares during the last quarter. Capital Management Corp VA purchased a new stake in LifeVantage in the 3rd quarter valued at about $5,073,000. Finally, HighTower Advisors LLC purchased a new stake in LifeVantage in the 3rd quarter valued at about $638,000. 35.32% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

LFVN has been the topic of several research analyst reports. Craig Hallum initiated coverage on shares of LifeVantage in a research report on Tuesday. They issued a "buy" rating and a $35.00 target price on the stock. Lake Street Capital started coverage on shares of LifeVantage in a research note on Thursday, December 19th. They set a "buy" rating and a $26.00 price objective for the company.

LifeVantage Stock Up 0.0 %

Shares of NASDAQ LFVN traded up $0.01 during midday trading on Friday, hitting $25.31. The stock had a trading volume of 134,842 shares, compared to its average volume of 112,642. LifeVantage Co. has a 1-year low of $5.22 and a 1-year high of $27.38. The company has a market capitalization of $316.88 million, a price-to-earnings ratio of 79.10 and a beta of 0.82. The company has a fifty day moving average price of $16.74 and a 200 day moving average price of $12.12.

LifeVantage (NASDAQ:LFVN - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.15 earnings per share for the quarter, meeting analysts' consensus estimates of $0.15. LifeVantage had a net margin of 2.11% and a return on equity of 29.24%. The firm had revenue of $47.21 million for the quarter.

LifeVantage Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were paid a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date of this dividend was Monday, December 2nd. LifeVantage's dividend payout ratio is presently 50.00%.

LifeVantage Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.